[go: up one dir, main page]

WO2005056054A3 - METHODS OF INHIBITING APOPTOSIS USING INDUCERS OF NF-κB - Google Patents

METHODS OF INHIBITING APOPTOSIS USING INDUCERS OF NF-κB Download PDF

Info

Publication number
WO2005056054A3
WO2005056054A3 PCT/US2004/040749 US2004040749W WO2005056054A3 WO 2005056054 A3 WO2005056054 A3 WO 2005056054A3 US 2004040749 W US2004040749 W US 2004040749W WO 2005056054 A3 WO2005056054 A3 WO 2005056054A3
Authority
WO
WIPO (PCT)
Prior art keywords
inducers
methods
inhibiting apoptosis
apoptosis
inhibiting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2004/040749
Other languages
French (fr)
Other versions
WO2005056054A2 (en
Inventor
Andrei V Gudkov
George Stark
Tao Lu
Lyudmila Burdelya
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cleveland Clinic Foundation
Original Assignee
Cleveland Clinic Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cleveland Clinic Foundation filed Critical Cleveland Clinic Foundation
Publication of WO2005056054A2 publication Critical patent/WO2005056054A2/en
Publication of WO2005056054A3 publication Critical patent/WO2005056054A3/en
Priority to US11/421,918 priority Critical patent/US7638485B2/en
Anticipated expiration legal-status Critical
Priority to US12/617,639 priority patent/US8106005B2/en
Priority to US12/617,653 priority patent/US8784840B2/en
Priority to US14/305,709 priority patent/US9296793B2/en
Priority to US15/049,953 priority patent/US9585939B2/en
Priority to US15/413,949 priority patent/US10406206B2/en
Priority to US16/527,770 priority patent/US11235028B2/en
Priority to US17/557,438 priority patent/US20220105155A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The therapeutic use of inducers of NF-κB activity in the treatment of NF-κB-mediated diseeases, conditions, and injuries is disclosed.
PCT/US2004/040749 2003-12-02 2004-12-02 METHODS OF INHIBITING APOPTOSIS USING INDUCERS OF NF-κB Ceased WO2005056054A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
US11/421,918 US7638485B2 (en) 2003-12-02 2006-06-02 Modulating apoptosis
US12/617,653 US8784840B2 (en) 2003-12-02 2009-11-12 Method for screening modulators of apoptosis
US12/617,639 US8106005B2 (en) 2003-12-02 2009-11-12 Modulating apoptosis
US14/305,709 US9296793B2 (en) 2003-12-02 2014-06-16 Modulating apoptosis
US15/049,953 US9585939B2 (en) 2003-12-02 2016-02-22 Protection against apoptosis from ionizing radiation
US15/413,949 US10406206B2 (en) 2003-12-02 2017-01-24 Protection against stress-mediated damage from ionizing radiation
US16/527,770 US11235028B2 (en) 2003-12-02 2019-07-31 Protection against stress-mediated damage from ionizing radiation
US17/557,438 US20220105155A1 (en) 2003-12-02 2021-12-21 Protection against stress-mediated damage from ionizing radiation

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US52646103P 2003-12-02 2003-12-02
US52649603P 2003-12-02 2003-12-02
US52666603P 2003-12-02 2003-12-02
US60/526,496 2003-12-02
US60/526,461 2003-12-02
US60/526,666 2003-12-02
US52646004P 2004-12-02 2004-12-02
US60/526,460 2004-12-02

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/040750 Continuation WO2005056055A2 (en) 2003-12-02 2004-12-02 METHODS OF PROTECTING AGAINST RADIATION USING INDUCERS OF NF-κB

Related Child Applications (3)

Application Number Title Priority Date Filing Date
PCT/US2004/040579 Continuation WO2005057218A2 (en) 2003-12-02 2004-12-02 Methods of identifying modulators of apoptosis from parasites and uses thereof
PCT/US2004/040753 Continuation WO2005056042A2 (en) 2003-12-02 2004-12-02 Methods of protecting against radiation using flagellin
US11/421,918 Continuation US7638485B2 (en) 2003-12-02 2006-06-02 Modulating apoptosis

Publications (2)

Publication Number Publication Date
WO2005056054A2 WO2005056054A2 (en) 2005-06-23
WO2005056054A3 true WO2005056054A3 (en) 2006-02-09

Family

ID=34682349

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/040749 Ceased WO2005056054A2 (en) 2003-12-02 2004-12-02 METHODS OF INHIBITING APOPTOSIS USING INDUCERS OF NF-κB

Country Status (1)

Country Link
WO (1) WO2005056054A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006069198A1 (en) 2004-12-22 2006-06-29 Cleveland Clinic Foundation Flagellin related polypeptides and uses thereof
ES2412237T3 (en) 2008-08-01 2013-07-10 Cleveland Biolabs, Inc. Methods to treat reperfusion injuries
MX361355B (en) 2011-01-10 2018-12-04 Cleveland Biolabs Inc Use of toll-like receptor agonist for treating cancer.
AU2015296555B2 (en) 2014-07-30 2020-05-21 Genome Protection, Inc. Flagellin compositons and uses
EP3206708B1 (en) 2014-10-16 2022-11-02 Cleveland Biolabs, Inc. Methods and compositions for the treatment of radiation-related disorders

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
EAVES-PYLES T D ET AL: "Salmonella flagellin-dependent proinflammatory responses are localized to the conserved amino and carboxyl regions of the protein.", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 15 DEC 2001, vol. 167, no. 12, 15 December 2001 (2001-12-15), pages 7009 - 7016, XP002341395, ISSN: 0022-1767 *
EAVES-PYLES T ET AL: "Flagellin, a novel mediator of Salmonella-induced epithelial activation and systemic inflammation: I kappa B alpha degradation, induction of nitric oxide synthase, induction of proinflammatory mediators, and cardiovascular dysfunction", JOURNAL OF IMMUNOLOGY, WILLIAMS & WILKINS CO, US, vol. 166, no. 2, 15 January 2001 (2001-01-15), pages 1248 - 1260, XP002210841, ISSN: 0022-1767 *
EGAN LAURENCE J ET AL: "IkappaB-kinasebeta-dependent NF-kappaB activation provides radioprotection to the intestinal epithelium.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 101, no. 8, 24 February 2004 (2004-02-24), pages 2452 - 2457, XP002341240, ISSN: 0027-8424 *
GRDINA DAVID J ET AL: "Relationships between cytoprotection and mutation prevention by WR-1065.", MILITARY MEDICINE. FEB 2002, vol. 167, no. 2 Suppl, February 2002 (2002-02-01), pages 51 - 53, XP008051184, ISSN: 0026-4075 *
HERBERT J M ET AL: "Involvement of u-PA in the anti-apoptotic activity of TGF-beta for vascular smooth muscle cells", FEBS LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 413, no. 3, 1997, pages 401 - 404, XP002347628, ISSN: 0014-5793 *
JUNG CHUL W ET AL: "Antiproliferative effect of a vitamin D3 analog, EB1089, on HL-60 cells by the induction of TGF-beta receptor", LEUKEMIA RESEARCH, vol. 23, no. 12, December 1999 (1999-12-01), pages 1105 - 1112, XP002357507, ISSN: 0145-2126 *
KOENIG H-G ET AL: "TRANSFORMING GROWTH FACTOR BETA 1 ACTIVATES NFKB IN RAT PHEOCHROMOCYTOMA PC 12 CELLS", ABSTRACTS OF THE SOCIETY FOR NEUROSCIENCE, SOCIETY FOR NEUROSCIENCE, WASHINGTON, DC, US, vol. 27, no. 1, 2001, pages 1244, XP008053612, ISSN: 0190-5295 *
MURLEY JEFFREY S ET AL: "Delayed cytoprotection after enhancement of Sod2 (MnSOD) gene expression in SA-NH mouse sarcoma cells exposed to WR-1065, the active metabolite of amifostine", RADIATION RESEARCH, vol. 158, no. 1, July 2002 (2002-07-01), pages 101 - 109, XP008051326, ISSN: 0033-7587 *
MURLEY JEFFREY S ET AL: "Delayed radioprotection by NFkappaB-mediated induction of Sod2 (MnSOD) in SA-NH tumor cells after exposure to clinically used thiol-containing drugs", RADIATION RESEARCH, vol. 162, no. 5, November 2004 (2004-11-01), pages 536 - 546, XP008051185, ISSN: 0033-7587 *
TALLANT THOMAS ET AL: "Flagellin acting via TLR5 is the major-activator of key signaling pathways leading to NF-kappaB and proinflammatory gene program activation in intestinal epithelial cells", BMC MICROBIOLOGY, vol. 4, no. 33, 23 August 2004 (2004-08-23), pages 1-24, XP002341239, ISSN: 1471-2180 *

Also Published As

Publication number Publication date
WO2005056054A2 (en) 2005-06-23

Similar Documents

Publication Publication Date Title
WO2005097119A3 (en) Pten inhibitors
AU2003249356A1 (en) Safe and effective nutritional supplement formulatins and associated regimens adapted to prevent and/or treat targeted diseases or medical or health conditions, and related methods
IL173123A0 (en) System and method for the photodynamic treatment of burns, wounds, and related skin disorders
AU2003300200A1 (en) Valve treatment catheter and methods
AU2003300791A1 (en) Combination therapy for the treatment of pain
AUPR839001A0 (en) Dosage form, device and methods of treatment
WO2005037323A3 (en) Use of gro to treat or prevent inflammation
ZA200410401B (en) Use of thio-oxindole derivatives in treatment of skin disorders
IL175974A0 (en) Methods of protecting against radiation using flagellin
WO2003049804A3 (en) Treatment of genitourinary tract disorders
WO2005013911A3 (en) Protective and therapeutic uses for tocotrienols
AU2003274963A1 (en) Mda-7 and free radicals in the treatment of cancer
WO2005056054A3 (en) METHODS OF INHIBITING APOPTOSIS USING INDUCERS OF NF-κB
AU2002352566A1 (en) Use of corrinoids in the treatment of skin diseases
AU2003221845A1 (en) Methods of treating medication-, substance-, disease-, and other medical condition-related sexual dysfunction
AU2003232699A1 (en) System and device for massage, pressure-treatment and heat-treatment of skin and parts of the body
EP1539100A4 (en) Composition and methods for the treatment of skin disorders
AU2003255843A1 (en) 1,3-thiazolin-4-ones as therapeutic compounds in the treatment of pain
AU2003244455A1 (en) Piperidylcarboxamide derivatives and their use in the treatment of tachykinim-mediated diseases
MXPA03000033A (en) Method of treating peripheral vascular diseases, peripheral neuropathies, and autonomic neuropathies.
IL164951A0 (en) The treatment of pain with lfendropil
AU2003219664A1 (en) Methods and therapeutic compositions in the treatment of advanced cancer
AU2003280137A1 (en) The use of 4-phenyl-substituted tetrahydroisoquinolines in the treatment of pain, migraine headaches and urinary incontinence
MXPA04000418A (en) Treatment of chronic pain with 3-heterocyclyl- and 3-cycloalkyl-3-aryloxypropanamines.
AU2003224147A1 (en) Pax-5-deficient pro-b-cells, methods of producing them and the use of such cells in human therapy

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 11421918

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWP Wipo information: published in national office

Ref document number: 11421918

Country of ref document: US

122 Ep: pct application non-entry in european phase